Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

813
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
813
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

786
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
786
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

936
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
936
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

746
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
746
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

570
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
570

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiometabolic Health in Pregnancy: Prevention, Management, and Long-Term Implications.

JACC. Advances·2026
Same author

Early Pregnancy Blood Pressure Trajectory Groups Predict Hypertensive Disorders of Pregnancy.

JACC. Advances·2026
Same author

Patient characteristics and incidence of in-hospital events in spontaneous coronary artery dissection and suspected concurrent Takotsubo syndrome: A report of the iSCAD registry.

American heart journal plus : cardiology research and practice·2026
Same author

Emulating a target trial of surgical removal of uterine fibroids on atherosclerotic cardiovascular disease.

Fertility and sterility·2026
Same author

Lost in Transition: Postpartum Care Discontinuity and Cardiovascular Risk After Hypertensive Pregnancy.

JACC. Advances·2026
Same author

Factors associated with a complicated hospital course in patients with spontaneous coronary artery dissection: a report of the iSCAD registry.

BMC cardiovascular disorders·2026

Related Experiment Video

Updated: Apr 26, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.3K

Cardiomyopathy in pregnancy.

Jennifer Lewey1, Jennifer Haythe1

  • 1Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY.

Seminars in Perinatology
|July 20, 2014
PubMed
Summary
This summary is machine-generated.

Peripartum cardiomyopathy, a rare but serious heart condition during pregnancy, affects maternal health significantly. Close monitoring by a multidisciplinary team is crucial for managing risks and improving outcomes.

Keywords:
CardiomyopathyHeart failurePeripartumPregnancy

More Related Videos

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
07:34

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System

Published on: May 5, 2018

11.0K
Noninvasive Electrocardiography in the Perinatal Mouse
04:36

Noninvasive Electrocardiography in the Perinatal Mouse

Published on: June 12, 2020

5.8K

Related Experiment Videos

Last Updated: Apr 26, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.3K
Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
07:34

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System

Published on: May 5, 2018

11.0K
Noninvasive Electrocardiography in the Perinatal Mouse
04:36

Noninvasive Electrocardiography in the Perinatal Mouse

Published on: June 12, 2020

5.8K

Area of Science:

  • Cardiology
  • Obstetrics
  • Maternal Health

Background:

  • Cardiomyopathy during pregnancy poses a significant risk, contributing to maternal mortality.
  • Peripartum cardiomyopathy (PPCM) is defined by its occurrence near childbirth.
  • African-American women experience higher incidence and adverse outcomes.

Purpose of the Study:

  • To summarize the risks and management of cardiomyopathy in pregnancy.
  • To highlight risk factors for adverse outcomes.
  • To emphasize the importance of multidisciplinary care.

Main Methods:

  • Review of existing literature on peripartum cardiomyopathy.
  • Identification of diagnostic criteria and risk factors.
  • Discussion of management strategies and team-based care.

Main Results:

  • Approximately 11% of maternal deaths are linked to cardiomyopathy during pregnancy.
  • About 50% of women with PPCM achieve full myocardial recovery within six months.
  • Severe complications, including heart failure and death, are not uncommon.

Conclusions:

  • Pregnant women with cardiomyopathy require vigilant monitoring by a multidisciplinary team.
  • Risk stratification using factors like baseline function and brain natriuretic peptide (BNP) levels is essential.
  • Early identification and management are key to improving maternal and fetal outcomes.